Stock Price Prediction

HRTX stock has a bullish outlook due to its recent legal victory, which strengthens its patent protection for CINVANTI until 2035, limiting generic competition. Analysts maintain a "Strong Buy" rating with a price target of $4, representing a 143.9% upside from its last close of $1.64. The stock's potential rebound is supported by this favorable ruling and its strategic positioning in the biotech sector.

HRTX stock is bearish due to its recent downgrade in price target from $5 to $4 by Needham, despite maintaining a "Strong Buy" rating. The stock closed at $1.28, significantly below the revised target, reflecting weak investor confidence. Additionally, while a favorable patent ruling temporarily boosted premarket trading, the long-term outlook remains uncertain amidst financial challenges.

The market consensus for HRTX's revenue in the upcoming quarter is projected to be approximately $34.25M USD.

The market consensus for HRTX's eps in the upcoming quarter is projected to be approximately $0.02 USD.